Although the underlying mechanisms causing this aberrant expression of HER3 in cancer cells, especially following EGFR-targeting treatment, is not fully elucidated, HER3 may be a potential target for anticancer therapy in these resistant cells. This evidence concerns the gene ERBB3 and cancer.